232 related articles for article (PubMed ID: 17408854)
21. Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42.
Maddalena A; Papassotiropoulos A; Müller-Tillmanns B; Jung HH; Hegi T; Nitsch RM; Hock C
Arch Neurol; 2003 Sep; 60(9):1202-6. PubMed ID: 12975284
[TBL] [Abstract][Full Text] [Related]
22. Biological markers in cerebrospinal fluid (CSF) and evaluation of in vitro effect of CSF on PC12 cell line viability in Alzheimer's disease.
Yaka E; Egrilmez MY; Keskinoglu P; Cavdar Z; Genc S; Genc K; Iyilikci L; Yener GG
Cell Biochem Funct; 2009 Aug; 27(6):395-401. PubMed ID: 19639578
[TBL] [Abstract][Full Text] [Related]
23. Usability of cerebrospinal fluid biomarkers in a tertiary memory clinic.
Brandt C; Bahl JC; Heegaard NH; Waldemar G; Johannsen P
Dement Geriatr Cogn Disord; 2008; 25(6):553-8. PubMed ID: 18536519
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia.
Engelborghs S; De Vreese K; Van de Casteele T; Vanderstichele H; Van Everbroeck B; Cras P; Martin JJ; Vanmechelen E; De Deyn PP
Neurobiol Aging; 2008 Aug; 29(8):1143-59. PubMed ID: 17428581
[TBL] [Abstract][Full Text] [Related]
25. CSF biomarker levels in early and late onset Alzheimer's disease.
Bouwman FH; Schoonenboom NS; Verwey NA; van Elk EJ; Kok A; Blankenstein MA; Scheltens P; van der Flier WM
Neurobiol Aging; 2009 Dec; 30(12):1895-901. PubMed ID: 18403055
[TBL] [Abstract][Full Text] [Related]
26. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
Parnetti L; Tiraboschi P; Lanari A; Peducci M; Padiglioni C; D'Amore C; Pierguidi L; Tambasco N; Rossi A; Calabresi P
Biol Psychiatry; 2008 Nov; 64(10):850-5. PubMed ID: 18395699
[TBL] [Abstract][Full Text] [Related]
27. Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease.
Sáez-Valero J; Fodero LR; Sjögren M; Andreasen N; Amici S; Gallai V; Vanderstichele H; Vanmechelen E; Parnetti L; Blennow K; Small DH
J Neurosci Res; 2003 May; 72(4):520-6. PubMed ID: 12704813
[TBL] [Abstract][Full Text] [Related]
28. Abnormalities of tau-protein and beta-amyloid in brain ventricle cerebrospinal fluid.
Talab R; Valis M; Rehak S; Krejsek J
Neuro Endocrinol Lett; 2009; 30(5):647-51. PubMed ID: 20035270
[TBL] [Abstract][Full Text] [Related]
29. [Alzheimer's disease as brain amyloidosis: diagnosis using cerebrospinal fluid abeta and tau].
Shoji M
Rinsho Byori; 2006 May; 54(5):503-8. PubMed ID: 16789421
[TBL] [Abstract][Full Text] [Related]
30. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
[TBL] [Abstract][Full Text] [Related]
31. Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides.
Höglund K; Hansson O; Buchhave P; Zetterberg H; Lewczuk P; Londos E; Blennow K; Minthon L; Wiltfang J
Neurodegener Dis; 2008; 5(5):268-76. PubMed ID: 18309230
[TBL] [Abstract][Full Text] [Related]
32. CSF neurofilaments in frontotemporal dementia compared with early onset Alzheimer's disease and controls.
Pijnenburg YA; Janssen JC; Schoonenboom NS; Petzold A; Mulder C; Stigbrand T; Norgren N; Heijst H; Hack CE; Scheltens P; Teunissen CE
Dement Geriatr Cogn Disord; 2007; 23(4):225-30. PubMed ID: 17290105
[TBL] [Abstract][Full Text] [Related]
33. Tau protein, phosphorylated tau protein and beta-amyloid42 in the cerebrospinal fluid of multiple sclerosis patients.
Valis M; Talab R; Stourac P; Andrys C; Masopust J
Neuro Endocrinol Lett; 2008 Dec; 29(6):971-6. PubMed ID: 19112391
[TBL] [Abstract][Full Text] [Related]
34. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease.
Hansson O; Buchhave P; Zetterberg H; Blennow K; Minthon L; Warkentin S
Neurobiol Aging; 2009 Feb; 30(2):165-73. PubMed ID: 17646035
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic value of CSF biomarker profile in frontotemporal lobar degeneration.
Kapaki E; Paraskevas GP; Papageorgiou SG; Bonakis A; Kalfakis N; Zalonis I; Vassilopoulos D
Alzheimer Dis Assoc Disord; 2008; 22(1):47-53. PubMed ID: 18317246
[TBL] [Abstract][Full Text] [Related]
36. Increased total-Tau levels in cerebrospinal fluid of pediatric hydrocephalus and brain tumor patients.
de Bont JM; Vanderstichele H; Reddingius RE; Pieters R; van Gool SW
Eur J Paediatr Neurol; 2008 Jul; 12(4):334-41. PubMed ID: 17951083
[TBL] [Abstract][Full Text] [Related]
37. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.
Parnetti L; Amici S; Lanari A; Romani C; Antognelli C; Andreasen N; Minthon L; Davidsson P; Pottel H; Blennow K; Gallai V
Neurol Sci; 2002 Sep; 23 Suppl 2():S95-6. PubMed ID: 12548360
[TBL] [Abstract][Full Text] [Related]
38. CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus.
Agren-Wilsson A; Lekman A; Sjöberg W; Rosengren L; Blennow K; Bergenheim AT; Malm J
Acta Neurol Scand; 2007 Nov; 116(5):333-9. PubMed ID: 17922727
[TBL] [Abstract][Full Text] [Related]
39. Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer's disease.
Skogseth R; Mulugeta E; Jones E; Ballard C; Rongve A; Nore S; Alves G; Aarsland D
Dement Geriatr Cogn Disord; 2008; 25(6):559-63. PubMed ID: 18536520
[TBL] [Abstract][Full Text] [Related]
40. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease.
Compta Y; Martí MJ; Ibarretxe-Bilbao N; Junqué C; Valldeoriola F; Muñoz E; Ezquerra M; Ríos J; Tolosa E
Mov Disord; 2009 Nov; 24(15):2203-10. PubMed ID: 19795497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]